Literature DB >> 27090419

Clinical impact of non-culprit lesions on 1-year mortality in very elderly patients with acute coronary syndrome.

Satoshi Higuchi1, Yusuke Kabeya2, Kenichi Matsushita1, Hiroki Taguchi1, Haruhisa Ishiguro1, Hideyasu Kohshoh1, Hideaki Yoshino3.   

Abstract

Preventive percutaneous coronary intervention (PCI) for non-culprit lesions after primary PCI remains controversial in patients with acute coronary syndrome (ACS). We analyzed whether PCI for non-culprit lesions would be associated with a better long-term prognosis in very elderly (≥85 years) patients. This study included 91 consecutive patients with ACS (mean age, 88.2 ± 3.0, 52 % male). We investigated the association of residual lesions with 1-year mortality. Culprit lesions affected the left anterior descending artery (LAD) in 50 patients, the left circumflex artery (LCx) in 29, and the right coronary artery (RCA) in 31. Residual lesions affected LAD in 20 cases, LCx in 22, and RCA in 21 patients. Residual lesions in LAD were associated with a higher 1-year mortality (p = 0.013), whereas residual lesions in LCx or RCA were not (p = 0.547 and 0.473, respectively). A Cox regression model demonstrated that patients with residual lesions in LAD had an increased risk of 1-year mortality compared with those without residual lesions (hazard ratio, 2.39; 95 % confidence interval, 1.16-4.96; p = 0.019). Therefore, the option to not treat residual lesions in LAD of patients with PCI may be associated with a higher 1-year mortality. Further studies are needed to confirm these findings.

Entities:  

Keywords:  Acute coronary syndrome; Percutaneous coronary intervention; Residual lesion; Very elderly

Mesh:

Year:  2016        PMID: 27090419     DOI: 10.1007/s00380-016-0833-y

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  20 in total

1.  Prima-vista multi-vessel percutaneous coronary intervention in haemodynamically stable patients with acute coronary syndromes: analysis of over 4.400 patients in the EHS-PCI registry.

Authors:  Timm Bauer; Uwe Zeymer; Matthias Hochadel; Helge Möllmann; Franz Weidinger; Ralf Zahn; Holger M Nef; Christian W Hamm; Jean Marco; Anselm K Gitt
Journal:  Int J Cardiol       Date:  2011-12-20       Impact factor: 4.164

2.  Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.

Authors:  Ran Kornowski; Roxana Mehran; George Dangas; Eugenia Nikolsky; Abid Assali; Bimmer E Claessen; Bernard J Gersh; S Chiu Wong; Bernhard Witzenbichler; Giulio Guagliumi; Dariusz Dudek; Martin Fahy; Alexandra J Lansky; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

3.  Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis.

Authors:  Pieter J Vlaar; Karim D Mahmoud; David R Holmes; Gert van Valkenhoef; Hans L Hillege; Iwan C C van der Horst; Felix Zijlstra; Bart J G L de Smet
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

4.  Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease.

Authors:  Lisette Okkels Jensen; Per Thayssen; Dóra Körmendiné Farkas; Mikkel Hougaard; Christian Juhl Terkelsen; Hans-Henrik Tilsted; Michael Maeng; Anders Junker; Jens Flensted Lassen; Erzsébet Horváth-Puhó; Henrik Toft Sørensen; Leif Thuesen
Journal:  EuroIntervention       Date:  2012-08       Impact factor: 6.534

5.  Prognostic impact of multivessel versus culprit vessel only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome.

Authors:  Ahmed Hassanin; Sorin J Brener; Alexandra J Lansky; Ke Xu; Gregg W Stone
Journal:  EuroIntervention       Date:  2015-07       Impact factor: 6.534

Review 6.  Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-analysis.

Authors:  Kevin R Bainey; Shamir R Mehta; Tony Lai; Robert C Welsh
Journal:  Am Heart J       Date:  2013-10-16       Impact factor: 4.749

7.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.

Authors:  T Killip; J T Kimball
Journal:  Am J Cardiol       Date:  1967-10       Impact factor: 2.778

Review 8.  Target-vessel versus multivessel revascularisation in ST-elevation myocardial infarction: a meta-analysis of randomised trials.

Authors:  Kiran Sarathy; Vinayak Nagaraja; Amit Kapur; Richard Szirt; Jwalant Raval; Guy D Eslick; David Burgess; A Robert Denniss
Journal:  Heart Lung Circ       Date:  2014-12-05       Impact factor: 2.975

9.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

10.  Randomized trial of preventive angioplasty in myocardial infarction.

Authors:  David S Wald; Joan K Morris; Nicholas J Wald; Alexander J Chase; Richard J Edwards; Liam O Hughes; Colin Berry; Keith G Oldroyd
Journal:  N Engl J Med       Date:  2013-09-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.